Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:HOTH NASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.05+2.3%$3.12$2.07▼$4.20$98.24M0.58101,898 shs9,450 shsHOTHHoth Therapeutics$1.45-1.0%$1.30$0.65▼$3.80$18.83M0.673.85 million shs377,938 shsSILOSilo Pharma$0.67+2.5%$0.65$0.41▼$3.37$6.26M0.31.58 million shs73,547 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%-3.56%0.00%-12.61%-5.99%HOTHHoth Therapeutics-0.68%+14.06%+22.69%+10.61%+47.47%SILOSilo Pharma+9.19%+1.33%-6.45%+9.92%-47.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.05+2.3%$3.12$2.07▼$4.20$98.24M0.58101,898 shs9,450 shsHOTHHoth Therapeutics$1.45-1.0%$1.30$0.65▼$3.80$18.83M0.673.85 million shs377,938 shsSILOSilo Pharma$0.67+2.5%$0.65$0.41▼$3.37$6.26M0.31.58 million shs73,547 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%-3.56%0.00%-12.61%-5.99%HOTHHoth Therapeutics-0.68%+14.06%+22.69%+10.61%+47.47%SILOSilo Pharma+9.19%+1.33%-6.45%+9.92%-47.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.00Buy$9.00202.01% UpsideHOTHHoth Therapeutics 3.00Buy$4.00173.97% UpsideSILOSilo Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HOTH, SILO, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/19/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/18/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/5/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/30/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/23/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa BiosciencesN/AN/AN/AN/A$0.59 per shareN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/ASILOSilo Pharma$70K87.64N/AN/A$1.12 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/12/2025 (Estimated)HOTHHoth Therapeutics-$8.19M-$1.07N/AN/AN/AN/A-114.32%-105.92%11/11/2025 (Estimated)SILOSilo Pharma-$4.39M-$1.05N/A∞N/A-6,798.61%-94.39%-68.62%11/10/2025 (Estimated)Latest HOTH, SILO, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/12/2025Q3 2025ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A8/13/2025Q2 2025SILOSilo PharmaN/A-$0.19N/A-$0.19N/A$0.02 million8/12/2025Q2 2025HOTHHoth Therapeutics-$0.27-$0.17+$0.10-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.898.89HOTHHoth TherapeuticsN/A27.5427.54SILOSilo PharmaN/A6.076.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%HOTHHoth Therapeutics7.08%SILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%HOTHHoth Therapeutics6.92%SILOSilo Pharma4.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableHOTHHoth Therapeutics413.26 million12.34 millionNot OptionableSILOSilo Pharma29.46 million8.99 millionNot OptionableHOTH, SILO, and ANIX HeadlinesRecent News About These Companies3 Under-the-Radar Biotechs Under $5 That Could Soar 200% (SILO)...September 9 at 6:45 PM | marketbeat.comSilo Pharma announces Japanese patent for PTSD drugSeptember 9 at 4:47 PM | msn.comSilo Pharma, Inc. Secures Japanese Patent for PTSD Treatment SPC-15 Through Columbia University PartnershipSeptember 9 at 9:31 AM | quiverquant.comQSilo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD DrugSeptember 9 at 9:10 AM | globenewswire.comSilo Pharma secures Australian patent covering licensed PTSD drug candidateSeptember 3, 2025 | msn.comSilo Flat on Securing Australian PatentSeptember 3, 2025 | baystreet.caSilo Pharma, Inc. Secures Patent for SPC-15, Advancing PTSD Treatment DevelopmentSeptember 3, 2025 | quiverquant.comQSilo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP PortfolioSeptember 3, 2025 | globenewswire.comSilo Pharmaâs Alzheimerâs Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal August 21, 2025 | markets.businessinsider.comSilo Pharma, Inc. Announces Publication of Preclinical Research on Alzheimer's Therapeutic SPC-14 in Alzheimer’s Research & TherapyAugust 21, 2025 | quiverquant.comQSilo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed JournalAugust 21, 2025 | globenewswire.comSilo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) PathwayAugust 19, 2025 | manilatimes.netMSilo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) PathwayAugust 19, 2025 | globenewswire.comSilo Pharma Second Quarter 2025 Earnings: US$0.19 loss per share (vs US$0.30 loss in 2Q 2024)August 15, 2025 | finance.yahoo.comSever Pharma expands work on ketamine implant with Silo PharmaAugust 11, 2025 | pharmatimes.comPSilo Pharma Leaps into Crypto with Corwin Yu at the Helm: A Shrewd Move or a Precarious Gamble?August 6, 2025 | nai500.comNSilo Pharma launches crypto treasury strategy with Bitcoin focusAugust 6, 2025 | investing.comSilo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury PlatformAugust 5, 2025 | globenewswire.comSilo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15July 16, 2025 | globenewswire.comSilo Pharma Secures Exclusive License for CNS PeptidesJuly 10, 2025 | tipranks.comSilo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026 - NasdaqJuly 9, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025HOTH, SILO, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.05 +0.07 (+2.35%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Hoth Therapeutics NASDAQ:HOTH$1.44 -0.02 (-1.03%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Silo Pharma NASDAQ:SILO$0.66 +0.02 (+2.54%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
